News

Zacks Investment Research on MSN3d
Vertex Down Around 9% in Three Months: Should You Buy, Sell or Hold the Stock?
Vertex Pharmaceuticals Incorporated VRTX stock has declined 8.9% in the past three months. The deterioration was due to soft first-quarter results, slower-than-expected uptake of its newer drugs as ...
Seeking Alpha3mon
Vertex: More Appealing At A Lower Price, But Don't Rush In (Rating Upgrade)
Vertex Software faces strong competition and slower growth, leading to a neutral rating. See why VERX stock remains pricey despite its $22B TAM.
Zacks Investment Research on MSN1d
Vertex Pharmaceuticals (VRTX) Rises As Market Takes a Dip: Key Facts
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $452.16, moving +1.56% from the previous trading session. This change outpaced the S&P 500's 0.11% loss on the day. Meanwhile, the ...
MarketWatch3y
Vectrus to merge with Vertex in a deal valuing Vertex at $2.1 billion
Vectrus Inc. announced Monday an agreement in which the facility and logistics services company will merge with Vertex Co., in a deal that values Vertex at about $2.1 billion.
The New York Times10mon
NYT Vertex Will Be Removed Aug. 29 - The New York Times
The New York Times will take down Vertex on Aug. 29. By Everdeen Mason My favorite part of this job is creating new things. I love the feeling of laboring with a group of kindred spirits to make ...
STAT1y
Vertex founder Joshua Boger on Casgevy, biotech, and Elon Musk - STAT
Vertex Pharmaceuticals made history Friday when it received regulatory approval for a medicine that could alter people’s DNA. While the company celebrated, its founder, Joshua Boger, looked on ...
Business Wire1y
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis - Business Wire
Vertex used a priority review voucher for this submission reducing the review time from 10 months to 6 months, resulting in a Prescription Drug User Fee Act (PDUFA) target action date of January 2 ...
Business Wire8mon
Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of ... - Business Wire
Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting ...
Reuters6mon
Vertex's painkiller results match placebo in study, shares tumble
Vertex Pharmaceuticals said on Thursday its experimental non-opioid drug met the main goal of a mid-stage study but showed little difference versus a placebo in reducing pain, sending its shares ...
Nasdaq3y
Why Vertex Is Striking Another Gene-Editing Deal With a Company Not Named CRISPR Therapeutics - Nasdaq
Vertex Pharmaceuticals has moved further into gene editing, this time through a deal with Mammoth Biosciences. Mammoth is a privately held biotech that's co-founded by CRISPR gene editing Pioneer ...
Reuters1y
Vertex's non-opioid drug reduces nerve pain in trial, shares hit record high - Reuters
Vertex Pharmaceuticals' non-opioid painkiller significantly decreased pain in patients with diabetes suffering from chronic nerve pain in a mid-stage trial, fueling efforts to develop a treatment ...